Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pb-203-RMX-VH
- Development stage
- Unknown
- Lead developer
- Radiomedix
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
Pb-203-RMX-VH (also known as 203Pb-RMX-VH-PIB) is an investigational radiopharmaceutical companion diagnostic developed by RadioMedix in collaboration with Vect-Horus. It consists of a DOTAM-modified peptide targeting vector (RMX-VH) that binds with high affinity to the low-density lipoprotein receptor (LDLR), which is overexpressed in various solid tumors, including glioblastoma multiforme (GBM) and pancreatic ductal adenocarcinoma (PDAC). The peptide is radiolabeled with lead-203 (Pb-203), a gamma-emitting radionuclide suitable for SPECT/CT imaging. This imaging agent is designed to cross the blood-brain barrier to evaluate biodistribution, dosimetry, and tumor targeting efficiency, serving as a companion diagnostic to select patients for targeted alpha therapy with its therapeutic counterpart, Pb-212-RMX-VH. It is currently in Phase 1 clinical development.
- Other names
- lead-203 RMX-VHlead203 RMX-VHlead 203 RMX-VHlead-203 RMX-VH-PIBlead203 RMX-VH-PIBlead 203 RMX-VH-PIB
02
Targets
LDLR (Low-density lipoprotein receptor)
Beyond the preview
Go deeper on Pb-203-RMX-VH.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pb-203-RMX-VH.